Immune Response Enhancement by in Vivo Administration of B7.2Ig, a Soluble Costimulatory Protein
| Autor: | Kwang Lee, Holly Swiniarski, Gary S. Gray, Andrew J. Dorner, Jenifer L. Thomas, Margot O'Toole, Knut Sturmhoefel, Stanley F. Wolf |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
CD4-Positive T-Lymphocytes
T-Lymphocytes T cell medicine.medical_treatment Immunology Immunoglobulins Biology Lymphocyte Activation Interferon-gamma Mice Th2 Cells Immune system Antigen Antigens CD medicine Animals Immunology and Allergy Mice Inbred BALB C Interleukin-13 Membrane Glycoproteins Histocompatibility Antigens Class I T-cell receptor Histocompatibility Antigens Class II T lymphocyte T helper cell Immunotherapy Th1 Cells Cell biology CTL medicine.anatomical_structure Solubility Antibody Formation Female Immunization B7-2 Antigen Interleukin-5 T-Lymphocytes Cytotoxic |
| Zdroj: | Clinical Immunology. 92:235-245 |
| ISSN: | 1521-6616 |
| Popis: | The identification of both class I- and class II-restricted tumor-associated peptides recognized by T cells has led to the test of these peptides as immunogens in experimental immunotherapy for cancer patients. However, optimal T cell activation requires signaling both through the T cell receptor for antigen and through costimulatory pathways. B7.1 and B7.2 are powerful costimulatory molecules expressed on the surface of antigen-presenting cells. Using a mouse model, we have sought to optimize costimulatory signals during antipeptide responses by administering a soluble form of B7.2 at the time of peptide immunization. Administration of B7. 2Ig fusion protein significantly enhanced T helper cell and CTL responses. These findings suggest that soluble forms of human B7.2 protein may provide a straightforward and practical method of supplying optimal costimulation during clinical immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect